COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
MedMira Reports First Quarter Results FY2024
MedMira Inc. (TSXV:MIR) has reported its financial results for the quarter ended October 31, 2023. The company achieved significant milestones during this period, including receiving US FDA 510(k) clearance for the HIV-2 claim on its Reveal® G4 Rapid HIV 1/2 antibody test. This approval positions MedMira as a key player in the HIV testing market and allows the company to expand its market share and revenue in the United States. -
COMMUNIQUÉ DE PRESSE
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
-
COMMUNIQUÉ DE PRESSE
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
-
COMMUNIQUÉ DE PRESSE
Update on MedMira’s Regulatory Path in Canada and the USA
-
COMMUNIQUÉ DE PRESSE
Progress Update on Securities
-
COMMUNIQUÉ DE PRESSE
MedMira Reports Third Quarter Results FY2023
-
COMMUNIQUÉ DE PRESSE
MedMira Reports Second Quarter Results FY2023
-
COMMUNIQUÉ DE PRESSE
Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada
-
COMMUNIQUÉ DE PRESSE
MedMira Enters into Partnership with Maternova for USA and Latin America
